Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy
K. G. Anderson, S. K. Oda, B. M. Bates, M. G. Burnett, M. Rodgers Suarez, S. L. Ruskin, P. D. Greenberg
This paper enhances ovarian cancer T cell therapy by engineering T cells to co-opt Fas ligand-mediated death signaling into pro-survival signals, improving persistence and therapeutic efficacy.
bioRxiv · Jul 30, 2021Immunology